UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1063) 1063
Book Chapter (46) 46
Newspaper Article (4) 4
Publication (4) 4
Magazine Article (3) 3
Dissertation (1) 1
Newsletter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (890) 890
trastuzumab (874) 874
life sciences & biomedicine (833) 833
humans (677) 677
breast cancer (649) 649
oncology (610) 610
female (539) 539
breast neoplasms - drug therapy (437) 437
erbb-2 protein (303) 303
metastasis (291) 291
receptor, erbb-2 - metabolism (283) 283
cancer (273) 273
chemotherapy (272) 272
breast neoplasms - pathology (243) 243
maytansine - analogs & derivatives (243) 243
her2 (231) 231
epidermal growth factor (223) 223
middle aged (222) 222
skin and connective tissue diseases (214) 214
antineoplastic agents - therapeutic use (203) 203
cancer therapies (199) 199
adult (177) 177
aged (176) 176
antibodies, monoclonal, humanized - therapeutic use (174) 174
tumors (174) 174
metastases (169) 169
care and treatment (162) 162
pertuzumab (161) 161
breast neoplasms - metabolism (159) 159
animals (158) 158
patients (157) 157
treatment outcome (153) 153
trastuzumab emtansine (151) 151
medicine & public health (150) 150
receptor, erbb-2 - antagonists & inhibitors (146) 146
antineoplastic combined chemotherapy protocols - therapeutic use (143) 143
trastuzumab - therapeutic use (140) 140
pharmacology & pharmacy (135) 135
receptor, erbb-2 - genetics (133) 133
t-dm1 (132) 132
clinical trials (130) 130
neoplasms (129) 129
analysis (124) 124
maytansine - therapeutic use (121) 121
lapatinib (120) 120
antibodies, monoclonal, humanized - administration & dosage (118) 118
trastuzumab - administration & dosage (118) 118
drug therapy (108) 108
research (106) 106
disease-free survival (105) 105
breast neoplasms - genetics (104) 104
metastatic breast cancer (104) 104
cell line, tumor (101) 101
antineoplastic agents (100) 100
monoclonal antibodies (99) 99
antimitotic agents (94) 94
medical prognosis (88) 88
antibodies (87) 87
antineoplastic agents - pharmacology (87) 87
cytotoxicity (87) 87
antibodies, monoclonal, humanized - adverse effects (85) 85
mice (85) 85
neoplasm metastasis (82) 82
kinases (80) 80
breast neoplasms - mortality (79) 79
antineoplastic agents - adverse effects (78) 78
molecular targeted therapy (76) 76
survival (76) 76
toxicity (76) 76
health aspects (75) 75
prognosis (74) 74
ado-trastuzumab emtansine (73) 73
neoplasms. tumors. oncology. including cancer and carcinogens (72) 72
aged, 80 and over (71) 71
trastuzumab - pharmacology (71) 71
review (69) 69
maytansine - adverse effects (67) 67
antibodies, monoclonal, humanized - pharmacology (66) 66
hematology, oncology and palliative medicine (66) 66
medical research (66) 66
xenograft model antitumor assays (66) 66
gastric cancer (64) 64
maytansine - administration & dosage (64) 64
antineoplastic agents, immunological - therapeutic use (62) 62
neoplasm staging (62) 62
trastuzumab - adverse effects (61) 61
proteins (60) 60
antineoplastic combined chemotherapy protocols - adverse effects (59) 59
cancer research (58) 58
stomach cancer (57) 57
antineoplastic agents - administration & dosage (55) 55
development and progression (55) 55
maytansine - pharmacology (55) 55
medicine, research & experimental (55) 55
research & experimental medicine (55) 55
biomarkers (53) 53
male (53) 53
medicine (53) 53
science & technology - other topics (51) 51
drug dosages (50) 50
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1108) 1108
French (7) 7
German (5) 5
Japanese (3) 3
Russian (3) 3
Chinese (2) 2
Czech (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 5/2012, Volume 69, Issue 5, pp. 1229 - 1240
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound via a stable thioether linker... 
Trastuzumab emtansine | Medicine & Public Health | Cancer Research | Oncology | Antibody–drug conjugate | T-DM1 | Breast cancer | Pharmacology/Toxicology | HER2 | Antibody-drug conjugate | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Antibodies, Monoclonal, Humanized - therapeutic use | Enzyme-Linked Immunosorbent Assay | Maytansine - analogs & derivatives | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Treatment Outcome | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Maytansine - pharmacology | Tandem Mass Spectrometry | Antibodies, Monoclonal, Humanized - pharmacokinetics | Breast Neoplasms - pathology | Antibodies, Monoclonal, Humanized - pharmacology | Maytansine - pharmacokinetics | Aged, 80 and over | Chromatography, Liquid | Adult | Female | Aged | Trastuzumab | Care and treatment | Oncology, Experimental | Antibodies | Polymerization | Liquid chromatography | Metastasis | Research | Antineoplastic agents | Chromatography | Viral antibodies | Antimitotic agents | Epidermal growth factor | Drug therapy | Mass spectrometry | Cancer | Index Medicus | Thrombocytopenia | Epidermal growth factor receptors | Liver | Data processing | Mass spectroscopy | Pharmacology | transaminase | ErbB-2 protein | trastuzumab | Immunogenicity | Microtubules | thioethers | Pharmacokinetics | Platelets | Enzyme-linked immunosorbent assay | Toxicology | Original
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2012, Volume 367, Issue 19, pp. 1783 - 1791
Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to trastuzumab emtansine... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Trastuzumab | Drugs | Dose-response relationship (Biochemistry) | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Comparative analysis | Thrombocytopenia | Chemotherapy | Epidermal growth factor | Vomiting | Diarrhea | Cytotoxicity | Nausea | Survival | ErbB-2 protein | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 06/2017, Volume 18, Issue 6, pp. 732 - 742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Capecitabine - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Response Evaluation Criteria in Solid Tumors | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Breast Neoplasms - chemistry | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Lapatinib | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Maytansine - analogs & derivatives | Anemia - chemically induced | Survival Rate | Thrombocytopenia - chemically induced | Trastuzumab - administration & dosage | Breast Neoplasms, Male - drug therapy | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Breast Neoplasms, Male - chemistry | Disease-Free Survival | Retreatment | Taxoids - administration & dosage | Vomiting - chemically induced | Aspartate Aminotransferases - blood | Capecitabine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Quinazolines - adverse effects | Aged | Breast Neoplasms, Male - pathology | Receptor, ErbB-2 - analysis | Bridged-Ring Compounds - administration & dosage | Care and treatment | Breast cancer | Metastasis | Patient outcomes | Analysis | Index Medicus
Journal Article
Journal Article
The AAPS journal, ISSN 1550-7416, 9/2014, Volume 16, Issue 5, pp. 994 - 1008
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate (ADC) therapeutic for treatment of human epidermal growth factor receptor 2 (HER2)-positive cancers... 
Biochemistry, general | Biotechnology | deconjugation | trastuzumab emtansine | Biomedicine | Pharmacy | antibody–drug conjugate | population pharmacokinetic model | T-DM1 | Pharmacology/Toxicology | antibody-drug conjugate | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Injections, Intravenous | Humans | Receptor, ErbB-2 - metabolism | Macaca fascicularis | Male | Antineoplastic Agents - administration & dosage | Breast Neoplasms - metabolism | Neoplasm Metastasis | Antibodies, Monoclonal, Humanized - administration & dosage | Antibodies, Monoclonal, Humanized - pharmacokinetics | Antibodies, Monoclonal, Humanized - blood | Biotransformation | Mass Spectrometry | Chromatography, Liquid | Female | Antineoplastic Agents - pharmacokinetics | Receptor, ErbB-2 - antagonists & inhibitors | Maytansine - blood | Reproducibility of Results | Maytansine - analogs & derivatives | Drug Stability | Rats | Breast Neoplasms - drug therapy | Rats, Sprague-Dawley | Maytansine - administration & dosage | Animals | Breast Neoplasms - pathology | Models, Biological | Maytansine - pharmacokinetics | Antineoplastic Agents - blood | Breast Neoplasms - blood | Trastuzumab | Enzymes | Analysis | Breast cancer | Liquid chromatography | Metastasis | Drug therapy | Enzyme-linked immunosorbent assay | Biopharmaceutics | Index Medicus
Journal Article